Floatz logo

Recombinant Human Interleukin-2

Follicular Lymphoma

Masonic Cancer Center, University of MinnesotaN/ADormant
D
28/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
65/ 100

Competitive context

128 Active assets in the Follicular Lymphoma cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Sun Yat-sen University
Phase 4BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 4BB
PREDNISONE TABLETS
Merck Sharp & Dohme LLC
Phase 4BB
(+)-VINCRISTINE
Merck Sharp & Dohme LLC
Phase 4BB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Merck Sharp & Dohme LLC
Phase 4BB

View all 50 →

Same molecule, other indications

Recombinant Human Interleukin-2 is also rated in:

non-Hodgkin lymphomaDormant
B
Indicative ·
60 / 100
View asset →
Brain Injury, AcuteDormant
B
Indicative ·
57 / 100
View asset →
LeukemiaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →